SG10201803187VA - Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof - Google Patents
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereofInfo
- Publication number
- SG10201803187VA SG10201803187VA SG10201803187VA SG10201803187VA SG10201803187VA SG 10201803187V A SG10201803187V A SG 10201803187VA SG 10201803187V A SG10201803187V A SG 10201803187VA SG 10201803187V A SG10201803187V A SG 10201803187VA SG 10201803187V A SG10201803187V A SG 10201803187VA
- Authority
- SG
- Singapore
- Prior art keywords
- immunogenic compositions
- capsular saccharide
- saccharide antigens
- conjugated capsular
- conjugated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461929547P | 2014-01-21 | 2014-01-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201803187VA true SG10201803187VA (en) | 2018-05-30 |
Family
ID=52630420
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201803187VA SG10201803187VA (en) | 2014-01-21 | 2015-01-15 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
SG11201604728XA SG11201604728XA (en) | 2014-01-21 | 2015-01-15 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201604728XA SG11201604728XA (en) | 2014-01-21 | 2015-01-15 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
Country Status (28)
Country | Link |
---|---|
US (1) | US9492559B2 (en) |
EP (3) | EP3096785B1 (en) |
JP (4) | JP6335326B2 (en) |
KR (4) | KR20220080201A (en) |
CN (4) | CN114848805A (en) |
AR (1) | AR099445A1 (en) |
AU (4) | AU2015208821B2 (en) |
BR (1) | BR112016015525A2 (en) |
CA (3) | CA3206112A1 (en) |
DK (1) | DK3096785T3 (en) |
ES (1) | ES2820824T3 (en) |
FR (2) | FR22C1028I1 (en) |
HU (3) | HUE051728T2 (en) |
IL (5) | IL296681A (en) |
MX (4) | MX2016009470A (en) |
NO (2) | NO2022021I1 (en) |
NZ (5) | NZ721943A (en) |
PE (2) | PE20161095A1 (en) |
PH (2) | PH12016501243B1 (en) |
PL (1) | PL3096785T3 (en) |
PT (1) | PT3096785T (en) |
RU (1) | RU2771293C2 (en) |
SA (1) | SA516371506B1 (en) |
SG (2) | SG10201803187VA (en) |
SI (1) | SI3096785T1 (en) |
TW (4) | TWI715285B (en) |
WO (1) | WO2015110941A2 (en) |
ZA (1) | ZA201603925B (en) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6824997B1 (en) | 1998-09-18 | 2004-11-30 | Binax, Inc. | Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies |
US9134303B1 (en) | 1998-08-25 | 2015-09-15 | Alere Scarborough, Inc. | ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto |
CN102716480B (en) | 2005-04-08 | 2023-03-21 | 惠氏有限责任公司 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
NZ704490A (en) | 2012-08-16 | 2017-07-28 | Pfizer | Glycoconjugation processes and compositions |
CA2937190A1 (en) * | 2014-01-21 | 2015-07-30 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
RU2771293C2 (en) | 2014-01-21 | 2022-04-29 | Пфайзер Инк. | Immunogenic compositions containing conjugated capsule saccharide antigens and their use |
US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
AU2015208820B2 (en) * | 2014-01-21 | 2020-05-14 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
AU2016207820B2 (en) * | 2015-01-15 | 2020-12-17 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
JP6882193B2 (en) * | 2015-04-28 | 2021-06-02 | バイオロジカル イー リミテッド | Methods for Separating Proteins and Other Impurities from Microbacterial Capsular Polysaccharides |
SG10202101887WA (en) * | 2015-05-04 | 2021-03-30 | Pfizer | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
TWI684460B (en) * | 2015-07-21 | 2020-02-11 | 美商輝瑞股份有限公司 | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
GB201518684D0 (en) * | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
EP3377098A1 (en) | 2015-11-20 | 2018-09-26 | Pfizer Inc | Immunogenic compositions for use in pneumococcal vaccines |
CN106110316A (en) * | 2016-06-27 | 2016-11-16 | 北京智飞绿竹生物制药有限公司 | A kind of preparation method of streptococcus pneumoniae conjugate combination-vaccine |
KR102467074B1 (en) * | 2016-08-05 | 2022-11-11 | 사노피 파스퇴르 인코포레이티드 | Polyvalent pneumococcal polysaccharide-protein conjugate composition |
BR112019001971A2 (en) * | 2016-08-05 | 2019-05-07 | Sanofi Pasteur, Inc. | multivalent pneumococcal polysaccharide-protein conjugate composition |
AR109621A1 (en) * | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | FORMULATIONS OF VACCINES AGAINST GLUCOCONJUGADOS OF EXPEC |
CN108144052A (en) * | 2016-12-02 | 2018-06-12 | 武汉博沃生物科技有限公司 | Streptococcus pneumoniae polysaccharides-protein conjugate and its preparation method and purposes |
KR20190103256A (en) | 2016-12-30 | 2019-09-04 | 수트로박스, 인코포레이티드 | Polypeptide-antigen conjugates with unnatural amino acids |
BR112019014833A2 (en) * | 2017-01-20 | 2020-04-14 | Pfizer | immunogenic compositions for use in pneumococcal vaccines |
US11197921B2 (en) | 2017-01-31 | 2021-12-14 | Merck Sharp & Dohme Corp. | Methods for making polysaccharide-protein conjugates |
US20200222550A1 (en) * | 2017-01-31 | 2020-07-16 | Merck Sharp & Dohme Corp. | Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f |
WO2018144799A1 (en) | 2017-02-03 | 2018-08-09 | SCHADECK, Eva, Barbara | Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof |
BR112019017560A2 (en) * | 2017-02-24 | 2020-04-07 | Merck Sharp & Dohme | enhancement of immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates |
AU2018225083B2 (en) * | 2017-02-24 | 2023-06-01 | Merck Sharp & Dohme Llc | Pneumococcal conjugate vaccine formulations |
US10688170B2 (en) * | 2017-06-10 | 2020-06-23 | Inventprise, Llc | Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity |
US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
JP7281207B2 (en) * | 2017-08-14 | 2023-05-25 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | Protein having pneumococcal encapsulation activity and method of use |
US20200360500A1 (en) * | 2017-08-16 | 2020-11-19 | Merck Sharp & Dohme Corp. | Pneumococcal conjugate vaccine formulations |
AU2018328037B2 (en) * | 2017-09-07 | 2024-03-07 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
US11491216B2 (en) | 2017-09-07 | 2022-11-08 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
CA3074711A1 (en) | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
CA3074703A1 (en) * | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
KR20230130153A (en) * | 2017-12-06 | 2023-09-11 | 머크 샤프 앤드 돔 엘엘씨 | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
CA3089007A1 (en) | 2018-02-05 | 2019-08-08 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US11147864B2 (en) * | 2018-02-05 | 2021-10-19 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
BR112020021296A2 (en) * | 2018-04-18 | 2021-01-26 | Sk Bioscience Co., Ltd. | capsular polysaccharide of streptococcus pneumoniae and its immunogenic conjugate |
EP3787674A4 (en) * | 2018-04-30 | 2022-01-26 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres |
JP7397000B2 (en) | 2018-04-30 | 2023-12-12 | メルク・シャープ・アンド・ドーム・エルエルシー | Method for providing a homogeneous solution of lyophilized mutant diphtheria toxin in dimethyl sulfoxide |
US20210252125A1 (en) * | 2018-04-30 | 2021-08-19 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates |
MX2020014118A (en) * | 2018-07-04 | 2021-06-18 | Vaxcyte Inc | Improvements in immunogenic conjugates. |
WO2020009462A1 (en) * | 2018-07-06 | 2020-01-09 | 주식회사 유바이오로직스 | Multivalent immunogenic composition comprising polysaccharide-protein conjugates, and vaccine comprising same for preventing disease caused by streptococcus pneumoniae |
US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
US11103567B2 (en) | 2018-12-06 | 2021-08-31 | Academia Sinica | Glycoconjugate vaccines, preparation method and uses thereof |
EP3893926A1 (en) | 2018-12-12 | 2021-10-20 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
BR112021011961A8 (en) | 2018-12-19 | 2023-02-07 | Merck Sharp & Dohme | COMPOSITIONS COMPRISING POLYSACCHARIDE-PROTEIN CONJUGATES OF STREPTOCOCCUS PNEUMONIAE AND METHODS OF USE THEREOF |
WO2020152706A1 (en) * | 2019-01-21 | 2020-07-30 | Biological E Limited | Multivalent pneumococcal conjugate vaccine compositions |
WO2020157772A1 (en) * | 2019-01-28 | 2020-08-06 | Biological E Limited | Multivalent pneumococcal polysaccharide-protein conjugate vaccine compositions |
JP7239509B6 (en) * | 2019-02-22 | 2023-03-28 | ファイザー・インク | Method for purifying bacterial polysaccharides |
US20220265803A1 (en) * | 2019-07-31 | 2022-08-25 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
WO2021165847A1 (en) | 2020-02-21 | 2021-08-26 | Pfizer Inc. | Purification of saccharides |
EP4232593A1 (en) | 2020-10-22 | 2023-08-30 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
JP2023549736A (en) | 2020-11-10 | 2023-11-29 | ファイザー・インク | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US20220387576A1 (en) | 2021-05-28 | 2022-12-08 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
CN115721709A (en) * | 2021-08-27 | 2023-03-03 | 康希诺生物股份公司 | Preparation method of pneumococcal conjugate vaccine |
WO2023218322A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Process for producing of vaccine formulations with preservatives |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4356170A (en) * | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4686102A (en) * | 1984-04-12 | 1987-08-11 | American Cyanamid Company | Multivalent pneumococcal vaccine and preparation thereof |
US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
DE3841091A1 (en) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE |
ES2055785T3 (en) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | SYNTHETIC PEPTIDES AND THEIR USE AS UNIVERSAL VEHICLES FOR THE PREPARATION OF IMMUNOGENOUS CONJUGATES SUITABLE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES. |
US5334379A (en) | 1989-07-14 | 1994-08-02 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
IT1237764B (en) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES. |
SE466259B (en) | 1990-05-31 | 1992-01-20 | Arne Forsgren | PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE |
DE69113564T2 (en) | 1990-08-13 | 1996-05-30 | American Cyanamid Co | Bordetella pertussis fiber hemagglutinin as a carrier for conjugated vaccine. |
CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
KR950700081A (en) | 1992-02-11 | 1995-01-16 | W 로우 죤 | Dual Carrier Immunogenic Constructs |
IT1262896B (en) | 1992-03-06 | 1996-07-22 | CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES. | |
JP3506431B2 (en) | 1992-05-06 | 2004-03-15 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Diphtheria toxin receptor binding domain |
CZ282235B6 (en) | 1992-06-25 | 1997-06-11 | Smithkline Beecham Biologicals (S.A.) | Inoculation substance, process of its preparation and use |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
ATE280235T1 (en) | 1993-03-05 | 2004-11-15 | Wyeth Corp | PLASMID FOR PRODUCING CRM PROTEIN AND DIPHTHERIA TOXIN |
PT812593E (en) | 1993-03-23 | 2002-01-30 | Smithkline Beecham Biolog | VACCINES CONTAINING 3-O-DEACILED MONOPHOSPHALOR-LIPID IN ITS COMPOSITION |
AU678613B2 (en) | 1993-09-22 | 1997-06-05 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
PT772619E (en) | 1994-07-15 | 2006-10-31 | Univ Iowa Res Found | OLIGONUCLEOTIDOS IMUNOMODULADORES |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
WO1996029094A1 (en) | 1995-03-22 | 1996-09-26 | Andrew Lees | Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents |
US5714354A (en) * | 1995-06-06 | 1998-02-03 | American Home Products Corporation | Alcohol-free pneumococcal polysaccharide purification process |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
JP2001513776A (en) | 1997-02-28 | 2001-09-04 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Use of nucleic acids containing unmethylated CpG dinucleotides in the treatment of LPS-related disorders |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
ATE370740T1 (en) | 1997-05-20 | 2007-09-15 | Ottawa Health Research Inst | METHOD FOR PRODUCING NUCLEIC ACID CONSTRUCTS |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
AU760549B2 (en) | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
CA2325939A1 (en) | 1998-04-09 | 1999-10-21 | Martin Friede | Vaccine |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
EP1588714A2 (en) | 1998-10-16 | 2005-10-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant systems and vaccines |
AU776828B2 (en) | 1998-12-21 | 2004-09-23 | Medimmune, Llc | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
DE69938670D1 (en) | 1998-12-23 | 2008-06-19 | Id Biomedical Corp | STREPTOCOCCUS ANTIGENE |
AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
EP2204186B1 (en) | 1999-02-17 | 2016-04-06 | CSL Limited | Immunogenic complexes and methods relating thereto |
EP1034792A1 (en) * | 1999-03-11 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Intranasal delivery of pneumococcal polysaccharide vaccines |
PL355178A1 (en) | 1999-03-19 | 2004-04-05 | Smithkline Beecham Biologicals S.A. | Vaccine |
US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
CZ303515B6 (en) | 1999-04-19 | 2012-11-07 | Smithkline Beecham Biologicals S. A. | Adjuvant compositions |
HUP0203817A3 (en) | 1999-09-24 | 2004-07-28 | Smithkline Beecham Biolog | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
JP2003509473A (en) | 1999-09-24 | 2003-03-11 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | vaccine |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
CN101260149B (en) | 2000-06-20 | 2016-05-11 | 魁北克益得生物医学公司 | Sa |
GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
EP1425040A2 (en) | 2001-09-14 | 2004-06-09 | Cytos Biotechnology AG | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
US7262024B2 (en) | 2001-12-20 | 2007-08-28 | Id Biomedical Corporation | Streptococcus antigens |
CA2518669C (en) | 2003-03-13 | 2014-07-29 | Glaxosmithkline Biologicals S.A. | Purification process |
CA2519511A1 (en) | 2003-03-17 | 2004-09-30 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
EP2484374A1 (en) | 2004-07-18 | 2012-08-08 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
JP2008506683A (en) | 2004-07-18 | 2008-03-06 | コーリー ファーマシューティカル グループ, リミテッド | Methods and compositions for inducing innate immune responses |
GB0421083D0 (en) | 2004-09-22 | 2004-10-27 | Glaxosmithkline Biolog Sa | Purification process |
US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
PT3466982T (en) | 2005-04-08 | 2020-07-24 | Wyeth Llc | Separation of contaminants from streptococcus pneumoniae polysaccharide by ph manipulation |
CN102716480B (en) * | 2005-04-08 | 2023-03-21 | 惠氏有限责任公司 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US7709001B2 (en) * | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
ATE516816T1 (en) | 2005-06-27 | 2011-08-15 | Glaxosmithkline Biolog Sa | METHOD FOR PRODUCING VACCINES |
TW201350129A (en) * | 2005-12-22 | 2013-12-16 | Glaxosmithkline Biolog Sa | Streptococcus pneumoniae immunogenic composition comprising capsular saccharide conjugates, vaccine and kit comprising the same and uses thereof |
GB0607088D0 (en) * | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
ATE473289T1 (en) | 2006-10-10 | 2010-07-15 | Wyeth Llc | IMPROVED METHODS FOR SEPARATION OF STREPTOCOCCUS PNEUMONIAE-3-POLYSACCHARIDES |
ES2922132T3 (en) | 2007-03-23 | 2022-09-08 | Wyeth Llc | Abbreviated purification procedure for the production of capsular polysaccharides from Streptococcus pneumoniae |
AU2008265767B2 (en) * | 2007-06-20 | 2014-11-13 | Pfizer Ireland Pharmaceuticals | Modified polysaccharides for conjugate vaccines |
AU2008267208B2 (en) * | 2007-06-26 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
CA2757620C (en) * | 2009-04-30 | 2016-04-26 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
GB201003924D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
WO2011145108A2 (en) * | 2010-05-15 | 2011-11-24 | Serum Institute Of India Ltd. | Purification of capsular polysaccharides |
WO2012078482A1 (en) * | 2010-12-10 | 2012-06-14 | Merck Sharp & Dohme Corp. | Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions |
GB201103836D0 (en) | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
NZ704490A (en) * | 2012-08-16 | 2017-07-28 | Pfizer | Glycoconjugation processes and compositions |
CA2893343C (en) | 2012-12-20 | 2019-05-14 | Pfizer Inc. | Glycoconjugation process |
ITMI20130142A1 (en) * | 2013-01-31 | 2014-08-01 | Biosynth Srl | GLYCOCOUGUGAR VACCINES INCLUDING BASIC UNITS OF AN EXPRIMENT MOLECULAR CONSTRUCTED MULTIPLE EPITHOPES INCORPORATED |
CN103495161B (en) | 2013-10-08 | 2019-06-18 | 江苏康泰生物医学技术有限公司 | A kind of mixture and preparation method thereof of polynary pneumococcal capsular polysaccharide-protein conjugate |
RU2771293C2 (en) | 2014-01-21 | 2022-04-29 | Пфайзер Инк. | Immunogenic compositions containing conjugated capsule saccharide antigens and their use |
-
2015
- 2015-01-15 RU RU2019112411A patent/RU2771293C2/en active
- 2015-01-15 ES ES15708580T patent/ES2820824T3/en active Active
- 2015-01-15 PE PE2016001240A patent/PE20161095A1/en unknown
- 2015-01-15 PL PL15708580T patent/PL3096785T3/en unknown
- 2015-01-15 CA CA3206112A patent/CA3206112A1/en active Pending
- 2015-01-15 KR KR1020227018413A patent/KR20220080201A/en not_active Application Discontinuation
- 2015-01-15 EP EP15708580.4A patent/EP3096785B1/en active Active
- 2015-01-15 EP EP19190039.8A patent/EP3607966A1/en active Pending
- 2015-01-15 CN CN202210390931.1A patent/CN114848805A/en active Pending
- 2015-01-15 DK DK15708580.4T patent/DK3096785T3/en active
- 2015-01-15 SG SG10201803187VA patent/SG10201803187VA/en unknown
- 2015-01-15 KR KR1020167019819A patent/KR102157200B1/en active Application Filing
- 2015-01-15 CA CA3170344A patent/CA3170344C/en active Active
- 2015-01-15 NZ NZ721943A patent/NZ721943A/en unknown
- 2015-01-15 AU AU2015208821A patent/AU2015208821B2/en active Active
- 2015-01-15 CN CN201911153913.6A patent/CN110787290A/en active Pending
- 2015-01-15 JP JP2016559412A patent/JP6335326B2/en active Active
- 2015-01-15 WO PCT/IB2015/050315 patent/WO2015110941A2/en active Application Filing
- 2015-01-15 CN CN202210391127.5A patent/CN114887048A/en active Pending
- 2015-01-15 BR BR112016015525A patent/BR112016015525A2/en active Search and Examination
- 2015-01-15 CN CN201580015008.8A patent/CN106102770B/en active Active
- 2015-01-15 NZ NZ755770A patent/NZ755770A/en unknown
- 2015-01-15 SI SI201531405T patent/SI3096785T1/en unknown
- 2015-01-15 US US14/597,488 patent/US9492559B2/en active Active
- 2015-01-15 IL IL296681A patent/IL296681A/en unknown
- 2015-01-15 MX MX2016009470A patent/MX2016009470A/en unknown
- 2015-01-15 KR KR1020207026127A patent/KR20200108496A/en not_active Application Discontinuation
- 2015-01-15 KR KR1020237003231A patent/KR20230021167A/en not_active Application Discontinuation
- 2015-01-15 NZ NZ759686A patent/NZ759686A/en unknown
- 2015-01-15 NZ NZ755769A patent/NZ755769A/en unknown
- 2015-01-15 CA CA2937186A patent/CA2937186C/en active Active
- 2015-01-15 NZ NZ760783A patent/NZ760783A/en active IP Right Revival
- 2015-01-15 EP EP19190033.1A patent/EP3616716A3/en active Pending
- 2015-01-15 PE PE2021001277A patent/PE20212335A1/en unknown
- 2015-01-15 HU HUE15708580A patent/HUE051728T2/en unknown
- 2015-01-15 SG SG11201604728XA patent/SG11201604728XA/en unknown
- 2015-01-15 PT PT157085804T patent/PT3096785T/en unknown
- 2015-01-20 AR ARP150100151A patent/AR099445A1/en not_active Application Discontinuation
- 2015-01-20 TW TW108140928A patent/TWI715285B/en active
- 2015-01-20 TW TW104101834A patent/TWI682778B/en active
- 2015-01-20 TW TW106141204A patent/TWI679987B/en active
- 2015-01-20 TW TW109144993A patent/TWI748810B/en active
-
2016
- 2016-06-09 ZA ZA2016/03925A patent/ZA201603925B/en unknown
- 2016-06-23 PH PH12016501243A patent/PH12016501243B1/en unknown
- 2016-07-19 SA SA516371506A patent/SA516371506B1/en unknown
- 2016-07-20 MX MX2021000523A patent/MX2021000523A/en unknown
- 2016-07-20 MX MX2021000522A patent/MX2021000522A/en unknown
- 2016-07-20 IL IL246853A patent/IL246853B/en active IP Right Grant
- 2016-07-20 MX MX2021000520A patent/MX2021000520A/en unknown
-
2017
- 2017-11-30 AU AU2017268651A patent/AU2017268651B2/en active Active
-
2018
- 2018-04-27 JP JP2018087041A patent/JP7059095B2/en active Active
-
2019
- 2019-06-28 AU AU2019204623A patent/AU2019204623B2/en active Active
- 2019-10-22 IL IL270090A patent/IL270090B/en active IP Right Grant
-
2020
- 2020-06-29 JP JP2020111834A patent/JP7227943B2/en active Active
-
2021
- 2021-02-13 PH PH12021550318A patent/PH12021550318A1/en unknown
- 2021-04-11 IL IL282215A patent/IL282215B2/en unknown
- 2021-05-10 IL IL283058A patent/IL283058B2/en unknown
- 2021-07-23 AU AU2021206895A patent/AU2021206895B2/en active Active
-
2022
- 2022-06-09 HU HUS2200029C patent/HUS2200029I1/en unknown
- 2022-06-09 NO NO2022021C patent/NO2022021I1/en unknown
- 2022-06-09 FR FR22C1028C patent/FR22C1028I1/en active Active
- 2022-07-28 FR FR22C1040C patent/FR22C1040I1/en active Active
- 2022-07-28 HU HUS2200035C patent/HUS2200035I1/en unknown
- 2022-08-04 NO NO2022035C patent/NO2022035I1/en unknown
-
2023
- 2023-02-09 JP JP2023018389A patent/JP2023065429A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2200035I1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
ZA201903620B (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof | |
IL248239A0 (en) | Anti - her3 antibody - drug conjugates, compositions comprising same and uses thereof | |
IL254016A0 (en) | Therapeutic and prophylactic composition produced by microbiota | |
EP3142695A4 (en) | Compositions and methods of enhancing immunogenicity of polysaccharide-protein conjugates | |
IL251120B (en) | Immunogenic/therapeutic glycoconjugate compositions and uses thereof | |
ZA201608487B (en) | Dual adjuvant vaccine compositions, preparation and uses | |
GB201610599D0 (en) | Immunogenic Composition | |
PL3223796T3 (en) | Pharmaceutical compositions, preparation and uses thereof | |
ZA201608327B (en) | Curcumin-peptide conjugates and formulations thereof | |
GB201721582D0 (en) | S aureus antigens and immunogenic compositions | |
GB201614485D0 (en) | Immunogenic composition | |
IL271603A (en) | Immunogenic compositions | |
GB201604755D0 (en) | Immunogenic compositions | |
GB201911959D0 (en) | Immunogenic compositions and uses therefor | |
SG11202004167XA (en) | Immunogenic compositions and uses therefor | |
GB201712096D0 (en) | Immunogenic conjugates and use thereof | |
AU2014902031A0 (en) | Immunogenic vaccines and uses thereof |